Fresenius Medcare: stock falls with UBS downgrading stock

(CercleFinance.com) - UBS has downgraded its rating on Fresenius Medical Care shares from "buy" to "neutral", having slashed its target price for them from 68 euros to 38 euros, with the latter target price leaving the share with minimal upside potential of 2% for the German dialysis specialist.


"Whilst valuation is attractive, it is not compelling enough to offset the earnings and reimbursement uncertainty we expect to act as overhangs until next year," the broker explains.

The share is currently down over 4% at just under 36 euros.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.